Post by Marina Mesquida, MD MSc PhD

Uveitic Macular Edema (UME) patients have been facing an impossible choice for decades:  - Repeated local steroid injections (and the risk of glaucoma/cataracts). - Systemic immunomodulatory therapies (and the burden of systemic toxicity). Data suggests that there is a better way: targeting the key inflammatory driver interleukin-6 (IL-6) at the site of action. The result? Meaningful vision improvements, sustained retinal fluid resolution, and a safety profile that changes the game for patients who have limited therapeutic options. When deep understanding of disease biology meets precision medicine, breakthroughs happen. 👁️✨ Special thanks to Sascha Fauser for his unwavering support and to our fantastic colleagues and collaborators Meike Pauly-Evers Laura Steeples David Silverman Zeinab Barekati Dr Rachael Harlow Niamh Gould Eric Suhler Phoebe Lin Sumit S. Jacqueline Ackermann Dr. Stefan Scheidl Nilesh Mehta Christopher Brittain Zdenka Haskova MD, PhD William Holmes Robbie Peck Bénédicte Passemard Kate Hedigan Federica Storti Saima Muzaffar PhD André Vicente Angie Petherick Emma Harrell Daniela Willen Helen Hollands Daniel Di Giusto   To all of our colleagues in the uveitis and retina community: How might a local, non-steroid option reshape your clinical workflow? We welcome your perspectives. #ophthalmology #innovation #RocheInnovation